However, the synergistic effect of BRAF and EGFR inhibitors in trials using vemurafenib in combination with IRI and cetuximab in BRAF-mutant CRC patients showed positive results [217,218,219,220]. The gene discussed is BRAF; the disease is colorectal carcinoma.